Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05065021
Title Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

fallopian tube cancer

peritoneum cancer

ovarian endometrial cancer

ovarian serous carcinoma

Therapies

Bevacizumab + Dostarlimab-gxly + Niraparib

Bevacizumab + Niraparib

Bevacizumab + Dostarlimab-gxly + Paclitaxel

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.